Skip to main content
. 2022 Jul 28;14(8):1572. doi: 10.3390/pharmaceutics14081572

Figure 4.

Figure 4

Comparison of the A-11-LNPs with clinically relevant formulations. (A) Nluc expression in spleen and inguinal LN 24 h after intravenous administration of Nluc-mRNA-loaded formulations at a dose of 0.5 mg mRNA/kg. (B) Percentage of EGFP+ splenic DCs 24 h after the intravenous administration of EGFP-mRNA-loaded formulations at a dose of 0.5 mg mRNA/kg. (C) I-A/I-E expression in splenic DCs 24 h after intravenous administration of EGFP-mRNA-loaded formulations at a dose of 0.5 mg mRNA/kg. n = 3. ** p < 0.01.